Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 14/20 | 0.55 |
| ▸ | ACACA | Q13085 | 3/20 | 0.49 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20560961 | 1.00 | DUT (0.55) | DUTACACAACACB | |
| SCHEMBL20560837 | 0.87 | DUT (0.56) | DUTACACAACACB | |
| SCHEMBL20560838 | 0.87 | DUT (0.56) | DUTACACAACACB | |
| SCHEMBL20358360 | 0.85 | DUT (0.63) | DUTACACA | |
| SCHEMBL20358358 | 0.85 | DUT (0.63) | DUTACACA | |
| SCHEMBL20351480 | 0.84 | DUT (0.54) | DUTACACAACACB | |
| SCHEMBL21778456 | 0.82 | DUT (0.53) | DUTACACAACACB | |
| SCHEMBL20351687 | 0.82 | DUT (0.57) | DUTACACAACACB | |
| SCHEMBL21533971 | 0.82 | DUT (0.57) | DUTACACAACACB | |
| SCHEMBL20187881 | 0.81 | DUT (0.56) | DUTACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479531-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-10-25 | — | — | US | disclosed |
| US-20200270207-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
| US-10577321-B2 | Deoxyuridine triphosphatase inhibitors | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180334431-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479531-B2 | Deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | DUT 1/4885ACACA 1721/4885ACACB 1331/4885 |
| US-20200270207-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | DUT 1/4885ACACA 1721/4885ACACB 1331/4885 |
| US-10577321-B2 | Deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | DUT 1/4885ACACA 1721/4885ACACB 1331/4885 |
| US-20180334431-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | DUT 1/4885ACACA 1721/4885ACACB 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.